The most common risk of thrombolysis is post-thrombolytic bleeding, which can lead to increased intracranial pressure in the patient and, in severe cases, to the development of brain herniation, leading to the patient’s death. Thrombolysis can also lead to the dislodgement of small emboli and the patient’s re-infarction in other parts of the brain. Thrombolytic therapy must follow the contraindications to thrombolysis. Thrombolysis is not recommended if the patient has a previous history of intracranial hemorrhage, nor is it recommended for patients with subarachnoid hemorrhage. Patients with intracranial tumors or arteriovenous malformations, cerebral infarction, or cerebral embolism should also not be given thrombolysis to avoid the risk of post-thrombolytic hemorrhage. Patients should be given intravenous urokinase or alteplase at the time of thrombolysis, and the symptoms of neurological deficits can be significantly improved in some patients after successful thrombolysis.